A responsible read on FormBlends compounded tesamorelin starts with mechanism, side effects, access, and monitoring rather than promises. That frame keeps the discussion useful for patients without pretending the evidence is stronger than it is.
Last October, I was standing in a radiology clinic in Scottsdale watching a tech named Marcus pull up my DEXA scan results. He turned the monitor toward me and pointed at the visceral fat column. “One point eight pounds,” he said, tapping the number. “Not terrible. Not great for someone who lifts four days a week.” I was 49, 195 pounds, waist at 38 inches, and I’d been stuck there for over a year. The subcutaneous fat was fine. Lean mass was fine. The visceral compartment, the fat packed around my liver and intestines that I couldn’t see in any mirror, was the problem child.
This is the six-month report on what happened when my endocrinologist prescribed tesamorelin and routed it through a 503A compounding pharmacy.
Quick regulatory note: tesamorelin is FDA-approved under the brand name Egrifta for reducing visceral adipose tissue in HIV-infected patients with lipodystrophy. Using it for general age-related visceral fat in non-HIV patients is off-label. Compounded versions are prepared by licensed 503A pharmacies for individual patients based on a prescriber’s clinical judgment.
Why Visceral Fat Specifically
Before getting into the protocol, it helps to understand why visceral adipose tissue (VAT) gets singled out from all the other fat you carry. Not all adipose tissue behaves the same way metabolically. Subcutaneous fat, the fat you can pinch under your skin, is relatively metabolically inert at moderate levels. It stores energy. It insulates. It’s cosmetically annoying but not particularly dangerous in reasonable quantities.
Visceral fat is a different animal. It sits inside the peritoneal cavity, wrapping around the liver, pancreas, intestines, and kidneys. Unlike subcutaneous fat, VAT is highly metabolically active. It secretes inflammatory cytokines like IL-6 and TNF-alpha, contributes to hepatic insulin resistance by dumping free fatty acids directly into the portal vein, and correlates independently with cardiovascular disease risk even after adjusting for total body fat (Després, 2012). A 2010 study published in Annals of Internal Medicine found that visceral fat accumulation was associated with increased all-cause mortality even in individuals with a normal BMI (Kuk et al., 2006). In other words, you can look lean and still carry metabolically dangerous fat if it’s concentrated in the visceral compartment.
This is what made my DEXA scan frustrating. My total body fat percentage was unremarkable for a 49-year-old man. The problem was where the fat had chosen to live. And the standard advice of “eat less, move more” hadn’t budged that compartment in 14 months, despite consistent calorie tracking and four days a week of resistance training. Visceral fat can be stubbornly resistant to generalized caloric deficit in middle-aged men, particularly when hormonal shifts like declining growth hormone secretion are part of the picture (Vahl et al., 2005).
Why My Doctor Said Yes
Two things got him across the line.
First, the DEXA told a specific story. My body composition wasn’t globally off. It was off in one compartment. Subcutaneous fat was age-appropriate. Lean mass was reasonable. The visceral number was the outlier, and it’s the compartment most tightly linked to cardiometabolic risk in middle age.
Second, my metabolic markers were drifting in an ugly direction. Fasting insulin at 11.4. Triglyceride-to-HDL ratio of 2.9. Neither of those screams crisis, but both are the kind of numbers that quietly become diabetes if you ignore them long enough. My HbA1c was 5.5, sitting in that prediabetic gray zone that most doctors describe as “worth watching.” My doctor described it as “worth acting on before it becomes worth treating.”
Here’s the thing about tesamorelin: it has the most specific human data of any GHRH analog for visceral fat reduction. The HIV-lipodystrophy trials showed roughly 15 to 18 percent reduction in VAT over 26 weeks at 2 mg daily (Falutz et al., 2007). A subsequent Phase III trial published in the New England Journal of Medicine confirmed these findings in a larger cohort, with trunk fat reductions measured by CT scan averaging approximately 15 percent at 26 weeks (Falutz et al., 2010). Whether that translates cleanly to a non-HIV 49-year-old with metabolic syndrome features is exactly the question nobody can answer with certainty yet.
My doctor also pointed out that tesamorelin works through a distinct mechanism from caloric restriction alone. As a growth hormone-releasing hormone analog, it stimulates the pituitary to produce endogenous growth hormone in a pulsatile fashion, which then drives lipolysis preferentially in visceral adipose tissue. This is different from exogenous GH administration, which floods the system with supraphysiologic, non-pulsatile GH and carries a heavier side-effect burden including insulin resistance and fluid retention. Tesamorelin essentially asks your pituitary to do more of what it already does, just at a rate closer to what it managed a decade or two ago.
We agreed to a 26-week trial. If my visceral fat hadn’t moved meaningfully on DEXA, we’d stop. Simple as that.
The Protocol
- Dose: 2 mg subcutaneous, nightly
- Site: abdomen, rotating quadrants
- Compounded by: a licensed 503A pharmacy
- Concurrent changes: none. Same training, same diet, same supplements. I wanted to isolate the variable, not muddy the data.
- Labs every 8 weeks: IGF-1, fasting glucose, HbA1c, lipid panel, comprehensive metabolic
- DEXA: baseline, 12 weeks, 26 weeks
I deliberately kept everything else constant, which I know isn’t how most people approach this. The temptation is always to stack interventions: start the peptide, add two new supplements, overhaul the diet, throw in extra cardio. That approach might produce faster results, but you’ll never know what’s actually working. I wanted the cleanest signal possible from a single variable, even if it meant slower progress.
Weeks 1 Through 12: The Waist Starts Moving
The first month was boring. Nothing visible. Some mild flushing at the injection site during week one that went away. One headache on night three that never came back. IGF-1 at week four climbed from a baseline of 124 to 198, which is exactly what the pharmacology predicts. My doctor noted that this level was within the normal physiological range for a man in his 30s, which is roughly where tesamorelin aims to restore you. Anything above 300 would have prompted a dose reduction.
By week eight, something shifted. Waist dropped an inch, from 38 to 37. Bodyweight barely moved (down maybe a pound). But my pants were noticeably looser at the waist while still fitting at the thigh. That’s the kind of detail I wouldn’t have predicted, but it lines up perfectly with the visceral-fat-specific hypothesis: you’re losing fat from the inside out, not uniformly.
There was also a moment in week six I remember clearly. I was sitting at my desk after lunch, and I noticed I wasn’t getting the same post-meal bloating I’d been experiencing for months. It’s a small thing, and I hesitate to attribute it directly to VAT reduction because digestive comfort has a dozen possible explanations. But it was notable enough that I logged it.
The 12-week DEXA confirmed it. Visceral fat down 0.4 pounds. Total body fat down 1.1 pounds. Lean mass up 0.2 pounds. My doctor’s exact words: “The trajectory is working.”
Weeks 13 Through 26: Slower, But the Metabolic Numbers Are the Real Story
Progress decelerated, which I expected. Think of it like wringing out a towel: the first twist gives you a lot of water, the second twist less. Waist came down another half inch over the next 14 weeks, landing at 36.5. Bodyweight dropped two more pounds.
One benefit I noticed consistently: deeper sleep. GHRH analogs tend to do this, and it showed up every single night. Growth hormone is naturally released in its largest pulse during slow-wave sleep, and stimulating the GHRH axis appears to reinforce that architecture. A study by Steiger et al. (1992) found that GHRH administration increased slow-wave sleep duration in healthy subjects. More vivid dreams, too, which is a quirk I’ve seen on other peptides. My Oura ring data, for whatever it’s worth, showed a consistent increase in deep sleep percentage from roughly 14 percent to 19 percent of total sleep time over the 26 weeks. That’s a substantial shift in sleep architecture, and while I can’t prove causation, the timing was conspicuous.
But the 26-week numbers are what mattered.
DEXA results: visceral fat down 0.7 pounds total from baseline (about 39 percent). Total body fat down 2.4 pounds. Lean mass essentially preserved.
Labs: A1C dropped from 5.5 to 5.3. Fasting insulin came down from 11.4 to 8.6. Triglyceride-to-HDL ratio went from 2.9 to 2.1.
That last cluster of numbers was the entire point. The metabolic profile improved. The visceral fat reduction was directionally consistent with what the HIV-lipodystrophy literature shows, though I started with far less visceral fat to lose than most trial subjects. A 39 percent drop sounds dramatic until you realize I went from 1.8 pounds to 1.1 pounds. Context matters.
The fasting insulin improvement is the number I keep coming back to. An 11.4 to 8.6 drop represents a meaningful reduction in insulin resistance, and given that hyperinsulinemia is increasingly recognized as a driver of cardiometabolic disease rather than just a marker of it (Reaven, 2005), moving that number in the right direction matters more to me than the waist measurement.
What I Felt Versus What I Measured
These didn’t always line up, and I think that’s worth being honest about.
What I felt was better sleep, slightly faster recovery from heavy training days, and a low-grade sense of leanness in the abdominal region, especially noticeable when sitting down. None of those are reliable subjective signals of visceral fat reduction. I’m reporting my experience because it was my experience, not because it constitutes evidence.
What I measured was the DEXA data above, the lab improvements, and a waist circumference reduction of 1.5 inches at stable bodyweight. Those are the data points I trust. The rest is texture.
One thing I did not experience: any noticeable change in strength or gym performance. Some people report improved recovery and increased lean mass on tesamorelin. My lean mass gain was 0.2 pounds over 26 weeks, which is essentially noise. If you’re considering tesamorelin as a performance-enhancing compound, I’d temper those expectations significantly. Its clinical value, based on both the trial data and my own experience, is compartment-specific fat reduction, not anabolism.
Side Effects (the practical read)
The most commonly reported side effects of tesamorelin are injection-site reactions, joint pain, peripheral edema, and hyperglycemia. I had mild redness at the injection site during weeks one and two. No joint pain. No edema. My fasting glucose didn’t increase. My doctor was specifically watching for that because tesamorelin can drive insulin resistance in some patients, and catching it early was a non-negotiable part of our plan.
It’s worth noting that the Phase III trials reported hyperglycemia in approximately 4.5 percent of subjects on tesamorelin versus 1.3 percent on placebo (Falutz et al., 2010). That’s not a trivial signal. Growth hormone, by its nature, is a counter-regulatory hormone that opposes insulin action. The theoretical risk is that while you’re reducing visceral fat (which should improve insulin sensitivity), you’re simultaneously increasing GH levels (which can worsen it). In my case, the net effect was positive on all metabolic markers. But regular glucose and insulin monitoring is not optional with this compound. It’s the minimum responsible approach.
My honest assessment: the side effect profile was genuinely mild for me. But I’m a sample size of one, and “it was fine for me” is the laziest form of safety data there is.
What It Cost
The 26 weeks ran approximately $1,420 total through FormBlends compounded tesamorelin, including prescriber consults and compounding pharmacy fulfillment. That’s roughly half the cost of a brand-name Egrifta course. The comparison isn’t perfectly apples-to-apples, though: Egrifta is an FDA-approved manufactured product, and compounded tesamorelin is prepared by a 503A pharmacy for an individual patient prescription.
I should note that insurance covered none of this. Egrifta can sometimes be covered for HIV-lipodystrophy patients, but off-label use of compounded tesamorelin for general visceral fat reduction is a cash-pay situation across the board. Between the peptide itself, the DEXA scans (three at roughly $125 each), and the lab draws (three rounds at roughly $200 each), the total cost of the experiment was closer to $2,400 when you account for everything. That’s a meaningful expense, and it’s worth budgeting for the monitoring, not just the drug.
What Comes Next
I’m going off tesamorelin for at least three months. The goal is to see how much of the visceral fat improvement holds with training and nutrition alone. The HIV-lipodystrophy data suggests that VAT tends to re-accumulate after tesamorelin discontinuation (Falutz et al., 2010), which is concerning but not surprising. Any intervention that works through hormonal modulation rather than structural change (like, say, surgery) will tend to revert when you remove the stimulus. The question is whether concurrent lifestyle factors can slow or prevent that reversion.
If it holds, I’ll likely do a second 26-week cycle in 18 to 24 months. If it doesn’t, my doctor and I will have a different conversation, probably about whether semaglutide or tirzepatide should enter the picture for the metabolic side, with tesamorelin as a complementary tool.
I also did what I should have done before any of this: added two cardio sessions per week. Zone 2 work, 30 to 40 minutes, on a rower and an assault bike. The peptide gave me a finite window to see what’s possible. The training is what has to keep it. The boring truth is that a peptide can open a door, but walking through it still requires shoes.
Frequently Asked Questions
Is tesamorelin the same as generic growth hormone? No. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog, not growth hormone itself. It stimulates your pituitary gland to release its own GH in a pulsatile, physiological pattern. Exogenous GH, by contrast, delivers a flat dose of synthetic hormone that bypasses the pituitary entirely. The distinction matters for side-effect profiles, feedback loops, and the pattern of GH release, which affects downstream IGF-1 levels and tissue-specific effects.
How long does it take to see results? In my case, measurable changes on DEXA appeared at 12 weeks. Waist circumference began shifting around week eight. The clinical trials used 26-week endpoints. Most prescribers I’ve spoken with suggest committing to at least 16 weeks before evaluating whether tesamorelin is producing meaningful results for a given patient. Expecting visible changes in the first four weeks is probably unrealistic for most people.
Can I use tesamorelin without a prescription? Legally, no. Tesamorelin is a prescription-only compound. It requires a prescriber to evaluate your medical history, order appropriate labs, and write a prescription that a licensed pharmacy can fill. Any source selling tesamorelin without requiring a prescription is operating outside the legal framework, and you have no assurance of product identity, purity, or sterility.
Does tesamorelin affect blood sugar? It can. Growth hormone is a counter-regulatory hormone, meaning it opposes insulin’s action on glucose uptake. The clinical trials reported higher rates of hyperglycemia in the tesamorelin group compared to placebo. In my case, fasting glucose remained stable and fasting insulin actually improved, but this outcome isn’t guaranteed. Regular metabolic monitoring, specifically fasting glucose, fasting insulin, and HbA1c, is a necessary part of any tesamorelin protocol. Patients with existing type 2 diabetes or significant insulin resistance should discuss the risk-benefit balance carefully with their prescriber.
What’s the difference between compounded tesamorelin and Egrifta? Egrifta is the FDA-approved, commercially manufactured version of tesamorelin produced by Theratechnologies. Compounded tesamorelin is prepared by licensed 503A pharmacies based on individual prescriptions. The active molecule is the same. The differences lie in manufacturing oversight, regulatory pathway, and cost. Egrifta goes through FDA manufacturing inspections and carries an approved label. Compounded versions are regulated at the state pharmacy board level and prepared under Section 503A of the Federal Food, Drug, and Cosmetic Act. Cost for compounded versions tends to be significantly lower.
Will the fat come back if I stop? The available data suggests it tends to. In the extension phases of the HIV-lipodystrophy trials, visceral fat re-accumulated in subjects who were switched from tesamorelin to placebo (Falutz et al., 2010). This is consistent with the mechanism: you’re augmenting a hormonal signal, not permanently altering your fat cell biology. Whether lifestyle modifications like increased cardiovascular training and dietary optimization can attenuate the rebound is an open question and exactly what I’m testing during my three-month washout period.
Is tesamorelin safe for long-term use? Long-term safety data is limited. The longest published trial data extends to about 52 weeks. No serious safety signals emerged in that timeframe beyond the known hyperglycemia risk and transient injection-site reactions. However, any compound that raises IGF-1 levels warrants monitoring for potential effects on cell proliferation over time. My doctor requires an annual review of IGF-1 levels and a discussion of continued use versus discontinuation at each checkpoint. This is an area where the honest answer is “we don’t know yet,” and anyone who tells you otherwise is speculating beyond the data.
Not FDA-approved for general visceral fat reduction outside the HIV-lipodystrophy indication. Compounded tesamorelin is prescribed off-label and prepared by licensed 503A pharmacies for individual patients based on clinical judgment. This is not medical advice.
